Wholesome residing: That is what drives the mushroom growth
Mushrooms seem to be popping up everywhere these days. All while millions digest the idea that mushrooms can support the immune system, reduce inflammation, and help improve mood. Chaga, for example, even caught the attention of coffee drinkers, says Thrillist. “It’s a superfood that is said to prevent and slow cancer, reduce inflammation, lower blood pressure and sugar, boost immunity, and even relieve the side effects of medication. In the short term, it provides stress relief, stimulates cognitive function, and increases athletic endurance.” This is great news for mushroom related companies, including NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF), ATAI life sciences (NASDAQ: ATAI), Compass paths (NASDAQ: CMPS), Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) and Cybin Inc. (NEO: CYBN) (OTC: CLXPF).
In addition, according to The Food Institute, “Mushroom supplements, extracts, and protein powders, including chaga, lion’s mane, reishi, and shiitake, are growing in popularity. Functional drink offerings that include these supplements, such as mushroom coffee, are also expanded. “
NeonMind launches functional mushroom coffees as a dietary supplement in the USA
NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) just announced that it has launched its NeonMind-branded functional mushroom coffee products as a dietary supplement in the United States. The initial launch includes two ground coffee SKUs that can now be shipped anywhere in the United States. Two instant coffee SKUs are expected to be added within a month.
The new website for US sales is live at intl.neonmind.com and is powered by Shopify. Products can be purchased individually and ordered as a subscription for a 10% discount. The website has been designed to be mobile friendly and focused on a customer-centric strategy. Consumers can subscribe to NeonMind’s newsletter for the latest news, product releases, and recipe information.
Each of the functional mushroom blends and botanicals selected in NeonMind coffees contain adaptogens, which means that they work with the body to manage physical, mental, and emotional stressors. Functional mushroom specifically refers to types of mushrooms that have health benefits in addition to providing nutrients. Functional mushrooms found in NeonMind coffees, such as cordyceps, lion’s mane, reishi, and turkey tail; offer long-term physical, neurological, and immunological benefits.
The first launch will include two types of ground coffee. The Protect Blend is a Peruvian French vanilla coffee with medium roast, turkey tail, cordyceps, moringa extract and amla extract. These ingredients have proven benefits of stress relief, immune support, and cognitive support. The Focus Blend is a Peruvian Dark Roast Coffee with lion’s mane extract, Reishi extract, Gotu Kola extract and Brahmi extract. These ingredients are a healthy source of fungal polysaccharides with immunomodulating properties that help improve memory and cognitive function, increase alertness, support the immune system, and combat mental and physical stress. The company will shortly launch its two instant coffee blends in the United States as dietary supplements.
The nutritional supplements for NeonMind coffee follow all FDA regulations focusing on comprehensive GMP (Good Manufacturing Practices) to ensure the identity, purity, quality, strength and composition of nutritional supplements. NeonMind only uses certified organic mushroom extracts that go through the decoction process (traditional water boiling) to maximize the bioavailability of the product. NeonMind follows strict US pharmacopoeia guidelines for lead and other chemicals required by Proposition 65 for safe, daily use. All final production batches are sent to a third party laboratory for rigorous microbial testing in order for the copacker to release the product analysis certificate, which indicates the product is safe for the consumer market.
The global functional mushroom market was estimated at $ 25.4 billion in 2020 and is expected to experience an average annual growth rate of 8.44% over the forecast period 2021-2026, according to a report by Mordor Intelligence.
Other related developments around the markets are:
ATAI Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental illnesses announced the pricing of its increased initial public offering in the United States of 15,000,000 common shares at a price of $ 15.00 per share. All common stocks are being offered by atai. The gross proceeds of the offering, before the deduction of subscription discounts and commissions and other offering costs payable by atai, is expected to be $ 225.0 million. In addition, atai has given the syndicate banks a 30-day option to purchase up to a further 2,250,000 ordinary shares at the market price minus subscription discounts and commissions. The offer is expected to end on June 22, 2021, subject to customary closing conditions.
Compass paths, A psychiatry company committed to accelerating patient access to evidence-based innovations in mental health announced the use of psilocybin in its Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression completed to the 216 target patients. This is the largest psilocybin therapy study in the world to date. The study is a randomized, controlled, double-blind, dose-range study evaluating the safety and effectiveness of psilocybin therapy, comparing a 25 mg and 10 mg dose of COMP360 psilocybin with a 1 mg dose used in conjunction with psychological support of administered to specially trained therapists.
Mydecine innovation group has selected substance abuse and smoking cessation as the first target indications for its proprietary psychedelic molecule MYCO-004. MYCO-004 is a patch-administered tryptamine compound and its properties include short duration (less than two hours), transdermal, precise dosing, and long-term compound stability. Mydecine said it selected substance abuse disorder and smoking cessation for MYCO-004 as it addresses underserved and drastic treatment needs. The company found that 19.7 million American adults had an addiction disorder. Of these, 8.5 million suffer from both substance abuse disorder and mental health disorder.
Cybin Inc., A biotechnology company focused on psychedelic pharmaceutical therapies is pleased to announce that Adelia Therapeutics Inc., a wholly-owned subsidiary of Cybin, will commence with the 1st Contribution Agreement dated December 4, 2020 between Cybin, Cybin Corp., Cybin US Holdings Inc., a wholly owned subsidiary of Cybin, and all previous shareholders of Adelia. Positive preclinical results, achieved through various earn-out milestones, indicated that proprietary deuteration modifications in several leading new chemical drug candidates did not deuterate the pharmacodynamic properties and safety as assessed in in vitro toxicity tests not changed analogues.
Disclaimer / Except for the historical information contained herein, the matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results, performance or accomplishments expressed therein statements are implied. Winning Media is not registered with any financial or securities regulator and does not provide investment advice or recommendations to readers of this press release. In order to make specific investment decisions, readers should seek advice for themselves. NeonMind Biosciences Inc. paid three thousand five hundred dollars for advertising and marketing services distributed by Winning Media. Winning Media is only remunerated for its services in the form of cash. Winning Media owns ZERO shares in NeonMind Biosciences Inc.
Please click here for the full disclaimer.